Literature DB >> 8165871

EBV-immortalized isogenic human B-cell clones exhibit differences in DNA-protein complex formation on the BZLF1 and BRLF1 promoter regions among latent, lytic and TPA-activated cell lines.

H Cen1, J L McKnight.   

Abstract

The reactivation of Epstein-Barr virus from latency requires the transcriptional induction of the viral encoded lytic cycle initiator gene, BZLF1, and a concomitant switch from OriP to OriLyt directed viral DNA replication. To investigate the role of host cell factors in these events, a series of EBV-immortalized clonal lymphoblastoid cell lines (LCL) were derived from the spontaneous outgrowth of peripheral blood lymphocytes from a single EBV-seropositive individual. We show that the state of virus activation among this family of isogenic clonal LCL differs, suggesting that each B-cell clone expresses a different complement of cellular factors that influence the state of viral activation. As a first step in the identification of factors involved in EBV reactivation, nuclear extracts were prepared from tightly latent, spontaneously replicating and latent LCL treated with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and sodium butyrate. The extracts were used in gel mobility shift analyses to compare DNA-protein complex formation among a series of target DNA sequences, including OriLyt and promoter sequences from BZLF1 and BRLF1. The DNA-protein complex patterns were reproducible and indistinguishable among extracts obtained from the latent LCL, but differed from those observed in extracts obtained from the spontaneously replicating LCL, particularly in regard to the binding of a CREB protein to the BZLF1 promoter. Moreover, extracts prepared from LCL treated with TPA to induce virus reactivation resulted in the formation of complexes that differed from those prepared from the spontaneously replicating LCL. Taken together, these data suggest that B-cell factors govern the state of viral activation and that EBV may be reactivated by more than one pathway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165871     DOI: 10.1016/0168-1702(94)90073-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.

Authors:  T Ragoczy; L Heston; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.

Authors:  A L Adamson; D Darr; E Holley-Guthrie; R A Johnson; A Mauser; J Swenson; S Kenney
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Investigating genetic-and-epigenetic networks, and the cellular mechanisms occurring in Epstein-Barr virus-infected human B lymphocytes via big data mining and genome-wide two-sided NGS data identification.

Authors:  Cheng-Wei Li; Bo-Ren Jheng; Bor-Sen Chen
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

4.  Identification and characterization of ZIIBC, a complex formed by cellular factors and the ZII site of the Epstein-Barr virus BZLF1 promoter.

Authors:  I K Ruf; D R Rawlins
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

5.  The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

6.  Nanoparticle exposure reactivates latent herpesvirus and restores a signature of acute infection.

Authors:  Christine Sattler; Franco Moritz; Shanze Chen; Beatrix Steer; David Kutschke; Martin Irmler; Johannes Beckers; Oliver Eickelberg; Philippe Schmitt-Kopplin; Heiko Adler; Tobias Stoeger
Journal:  Part Fibre Toxicol       Date:  2017-01-10       Impact factor: 9.400

7.  The human ATF1 rs11169571 polymorphism associated with risk of nasopharyngeal carcinoma in Southern Chinese populations.

Authors:  Shutang Peng; Guo-Liang Huang; Nansong Xu; Yan Lu; Liuyan Zeng; Xin Li; Shengqun Luo; Xiaoming Lyu; Qiang Jiang; Tong Li; Zhiwei He
Journal:  Cancer Med       Date:  2019-03-23       Impact factor: 4.452

Review 8.  Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.

Authors:  Hongde Li; Jianmin Hu; Xiangjian Luo; Ann M Bode; Zigang Dong; Ya Cao
Journal:  Cancer Sci       Date:  2018-06-13       Impact factor: 6.716

9.  Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway.

Authors:  Chandrima Gain; Samaresh Malik; Shaoni Bhattacharjee; Arijit Ghosh; Erle S Robertson; Benu Brata Das; Abhik Saha
Journal:  PLoS Pathog       Date:  2020-02-24       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.